Acumen Pharmaceuticals, Inc.
ABOS
$2.99
-$0.18-5.54%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 2.43M | 11.74M | 20.53M | 118.93M | 124.21M |
| Gross Profit | -2.43M | -11.74M | -20.53M | -118.93M | -124.21M |
| SG&A Expenses | 18.63M | 18.51M | 18.95M | 19.30M | 19.78M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 105.42M | 114.61M | 123.83M | 138.23M | 143.98M |
| Operating Income | -105.42M | -114.61M | -123.83M | -138.23M | -143.98M |
| Income Before Tax | -105.04M | -113.28M | -121.34M | -133.35M | -136.67M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -105.04 | -113.28 | -121.34 | -133.35 | -136.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -105.04M | -113.28M | -121.34M | -133.35M | -136.67M |
| EBIT | -105.42M | -114.61M | -123.83M | -138.23M | -143.98M |
| EBITDA | -105.37M | -114.56M | -123.77M | -138.17M | -143.92M |
| EPS Basic | -1.63 | -1.86 | -2.00 | -2.21 | -2.27 |
| Normalized Basic EPS | -1.02 | -1.16 | -1.25 | -1.38 | -1.42 |
| EPS Diluted | -1.63 | -1.86 | -2.00 | -2.21 | -2.27 |
| Normalized Diluted EPS | -1.02 | -1.16 | -1.25 | -1.38 | -1.42 |
| Average Basic Shares Outstanding | 256.62M | 244.94M | 242.25M | 241.75M | 241.26M |
| Average Diluted Shares Outstanding | 256.62M | 244.94M | 242.25M | 241.75M | 241.26M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |